Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Authors
Perrotti, Danilo
Agarwal, Anupriya
Lucas, Claire
Narla, Goutham
Neviani, Paolo
Odero, Maria D.
Ruvolo, Peter P.
Verrills, Nicole M.
Publication Date
2019-07-17
Submitted date
2018-05-01

Metadata
Show full item record
Abstract
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis. [Abstract copyright: Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.]
Citation
Science translational medicine, volume 11, issue 501
URI
http://hdl.handle.net/10034/622468
Type
article
Description
From PubMed via Jisc Publications Router
History: received 2018-05-01, accepted 2019-05-09
Publication status: ppublish
Collections